Acumapimod

Drug Profile

Acumapimod

Alternative Names: BCT-197; BCT197A2201

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Mereo BioPharma; Novartis
  • Class Anti-inflammatories; Antibronchitics; Benzamides; Cyclopropanes; Pyrazoles; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Acute kidney injury

Most Recent Events

  • 13 Dec 2016 Mereo BioPharma has patent protection for Acumapimod in United Kingdom and USA
  • 01 Oct 2016 Mereo BioPharma completes a drug-interaction phase I trial in Healthy volunteers in the United Kingdom (NCT02926326)
  • 01 Sep 2016 Mereo BioPharma initiates a drug-interaction phase I trial in Healthy volunteers in the United Kingdom (NCT02926326)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top